Abstract:Concurrent-adjuvant chemoradiotherapy (CRT) became a recommended treatment for locoregionally advanced nasopharyngeal carcinoma (NPC) since the first report of significant survival benefit by the Intergroup-0099 Study. However, data on late toxicities are lacking. Previous reports from confirmatory trials (NPC-9901 and NPC-9902 Trials on N2-3 and T3-4N0-1 disease, respectively) concurred that this regimen could improve tumor control, but did not achieve significant gain in overall survival (OS) up to 5 years. Validation of the long-term therapeutic ratio is needed. All patients had histologically confirmed non-keratinizing carcinoma of the nasopharynx and stage III-IVB disease by AJCC classification (fifth edition). Focusing on patients irradiated with conventional-fractionation, the current study evaluated 218 patients randomly assigned to radiotherapy-alone (RT) and 223 patients to CRT using cisplatin in concurrence with RT, followed by adjuvant cisplatin plus fluorouracil. Only 4% patients were lost to follow-up; the median follow-up was 13.9 years.Tabled 1Abstract 98; Table 1Comparison of outcome - Chemoradiotherapy group versus Radiotherapy-alone groupEndpoints10-year actuarial rateHR (95% CI)P value #Overall failure-free rate62% vs 52%0.70 (0.53, 0.94)0.016Progression-free survival56% vs 44%0.71 (0.56, 0.92)0.008Overall survival60% vs 50%0.77 (0.59, 0.99)0.044Cancer-specific survival71% vs 60%0.67 (0.48, 0.92)0.014Locoregional failure-free rate85% vs 75%0.56 (0.35, 0.88)0.010Distant failure-free rate69% vs 66%0.82 (0.59, 1.15)0.25Late toxicity rate51% vs 48%1.16 (0.86, 1.56)0.34HR = hazard ratio; CI = confidence interval; # P values were calculated by log-rank test Open table in a new tab HR = hazard ratio; CI = confidence interval; # P values were calculated by log-rank test Regarding late toxicity, there was no significant difference in the latency to manifestation, damage at specific sites, and overall severity between the two groups. The mortality rate due to treatment toxicity was 4.0% vs 3.2%, incidental / unknown cause was 14.8% vs 12.8%. The increase in toxicities and non-cancer deaths observed in early years diminished with long follow-up, ultimately resulting in significant gain in OS. Further analyses on actual treatment showed that those with ≥2 concurrent cycles had significantly better locoregional control (86% vs 74%, P = 0.001) and those with ≥2 adjuvant cycles had better distant control (73% vs 64%, P = 0.019) than those with 0-1 cycles. Long-term results confirmed that adding concurrent cisplatin plus adjuvant cisplatin-fluorouracil to conventional-fractionated RT could significantly improve OS without excessive late toxicities for patients with locoregionally advanced NPC. However, better compliance and/or more potent therapy is needed for improving distant control.

Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma.

Phase Iii Study Comparing Standard Radiotherapy With Or Without Weekly Oxaliplatin In Treatment Of Locoregionally Advanced Nasopharyngeal Carcinoma: Preliminary Results

Preliminary Report of Randomized Phase Ii Clinical Study Comparing Standard Radiotherapy with or Without Weekly Oxaliplatin in Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma (Npc)

A Randomized Phase-II Clinical Control Study on Standard Radiotherapy in Combination with Weekly Oxaliplatin for Treatment of Loco-regional Advanced Nasopharyngeal Carcinoma

Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma

A Comparison of Weekly Versus 3-Weekly Cisplatin During Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma Using Intensity Modulated Radiation Therapy: a Matched Study.

Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Treatment Outcomes of a Prospective, Multicentric Clinical Study

Concurrent Chemoradiotherapy With/without Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Long‐term Results of Phase 3 Randomized Controlled Trial

Concurrent weekly docetaxel chemotherapy in combination with radiotherapy for stage III and IVA-B nasopharyngeal carcinoma.

Comparing Long-Term Survival and Late Toxicities of Different Sequential Chemotherapy Regimens with Intensity-Modulated Radiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Triweekly Versus Weekly Cisplatin Concurrent with Radiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Concurrent Chemoradiotherapy with 3-Weekly Versus Weekly Cisplatin in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3 Multicentre Randomised Controlled Trial (Chictr-Trc-12001979).

1108OChemotherapy plus local-regional radiotherapy versus chemotherapy alone in primary metastatic nasopharyngeal carcinoma: A randomized, open-label, phase III trial

10-Year Outcome on the Efficacy and Late Toxicities Attributed to the Addition of Concurrent-Adjuvant Chemotherapy for Stage III-IVB Nasopharyngeal Carcinoma (combined Analyses of the NPC-9901 and NPC-9902 Trials)

Adjuvant Chemotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: Long-term Results of a Phase 3 Multicentre Randomised Controlled Trial

Ten-year outcomes of survival and toxicity for a phase III randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma.

Comparison of Long-Term Survival and Toxicity of Cisplatin Delivered Weekly Versus Every Three Weeks Concurrently with Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma.

Progress Report of A Randomized Trial Comparing Long-Term Survival and Late Toxicity of Concurrent Chemoradiotherapy with Adjuvant Chemotherapy Versus Radiotherapy Alone in Patients with Stage Iii to Ivb Nasopharyngeal Carcinoma from Endemic Regions of China

Long-term efficacy analysis of radiotherapy and local management of metastases in patients with newly diagnosed oligometastatic nasopharyngeal carcinoma: A prospective, single-arm, single-center clinical study

Randomized Trial of Radiotherapy Versus Radiotherapy Concurrently with Weekly Cisplatin for Treatment of Locally Advanced Nasopharyngeal Carcinoma

Long-term survival, toxicities, and the role of chrono-chemotherapy with different infusion rates in locally advanced nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy: a retrospective study with a 5-year follow-up